KRAS and neoplasm: Mechanistic investigations showed mutant KRAS‐driven lactic acid increased the susceptibility to AICD of tumor‐specific cytotoxic T‐cells via NF‐κB inactivation, which might underlie the correlation between KRAS status and intratumoral cytotoxic CD8+ T‐cells.